NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
Clinical Trials
5 trialsNCT06518564 2026-01-07
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03503786 2023-11-13
MITO END-3
National Cancer Institute, Naples
Phase 2 Unknown
NCT03312114 2020-11-12
Anti-PD-L1 and SAbR for Ovarian Cancer
University of Texas Southwestern Medical Center
Phase 2 Terminated